相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Unravelling the pathogenesis of inflammatory bowel disease
R. J. Xavier et al.
NATURE (2007)
Predictors of medication adherence in inflammatory bowel disease
Jason P. Ediger et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Effect of sulphasalazine and balsalazide on histamine release from mast cells
K. H. Peh et al.
INFLAMMATION RESEARCH (2007)
The risks and the benefits of mesalazine as a treatment for ulcerative colitis
Alan C. Moss et al.
EXPERT OPINION ON DRUG SAFETY (2007)
PPAR gamma as a new therapeutic in inflammatory bowel diseases
L. Dubuquoy et al.
GUT (2006)
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and metaanalysis of observational studies
FS Velayos et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum
KA Kles et al.
INFLAMMATORY BOWEL DISEASES (2005)
Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?
PDR Higgins et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Utilization of health care resources by individuals with inflammatory bowel disease in the United States: A profile of time since diagnosis
T Longobardi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis
EV Loftus et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk
MD Rutter et al.
GUT (2004)
5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study
TP Van Staa et al.
GASTROENTEROLOGY (2004)
Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease
MJ Shale et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis
RJ Lancashire et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis
WJ Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis
JC Mansfield et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis
JRB Green et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses
W Kruis et al.
GUT (2001)
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
PW Lowry et al.
GUT (2001)
Hypersensitivity reaction to balsalazide
V Adhiyaman et al.
BRITISH MEDICAL JOURNAL (2000)
分享论文
